← Back to patent-cliff list
OLX-10010
Tier C — Watch / tradeOLX-10010
Olix Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：CTGF
Indications (approved)：皮肤增生性瘢痕, Pulmonary fibrosis, 年龄相关性黄斑变性, 湿性年龄相关性黄斑变性
Regional status
US
Phase II
2021-08-19
EU
No progress
2018-05-21
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of OLX-10010?
Approved indications include: 皮肤增生性瘢痕, Pulmonary fibrosis, 年龄相关性黄斑变性, 湿性年龄相关性黄斑变性.
When does the OLX-10010 patent expire?
No public expiry year is available for OLX-10010 yet; this page updates once verified.
How do I get a quote for OLX-10010 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07